Open AccessEffectiveness and safety of Yufengningxin for treating coronary heart disease angina
Author(s) -
Chao Liu,
Jing Bai,
Lanchun Liu,
Jialiang Gao,
Jie Wang
Publication year - 2020
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000023911
Subject(s) - medicine , angina , cochrane library , medline , randomized controlled trial , meta analysis , unstable angina , protocol (science) , coronary heart disease , intensive care medicine , physical therapy , alternative medicine , myocardial infarction , pathology , political science , law
Background: More than 11 million people suffer from coronary heart disease (CHD) angina in China, showing high morbidity and mortality rates. Yufengingxin (YFNX) is a commonly used Chinese patent medicine in CHD angina treatment. The purpose of this protocol is to evaluate the effectiveness and safety of YFNX for the treatment of CHD angina. Methods: A systematic search of randomized controlled trials related to the effectiveness and safety of YFNX in the treatment of CHD angina will be performed from relevant databases, including PubMed, Cochrane Library, EMBASE, Chinese National Knowledge Infrastructure (CNKI), Wanfang Database, Chinese Scientific Journal Database (VIP) and Chinese Biomedical Literature Database (CBM). We will screen all the literatures from the database inception to November 1, 2020. The data including study ID, study characteristics, methodological information, patients information, interventions, comparisons and outcomes will be extracted. The frequency and duration of angina attacks will be served as the primary outcome. Review Manager 5.3 and STATA 14.0 software will be used for data analysis. Conclusion: This systematic review will provide strong evidence for the effectiveness and safety of YFNX in the treatment of CHD angina. Trial registration number: INPLASY2020110040.